CEBP CTRC-AACR San Antonio Breast Cancer Symposium 2008 Conference on Cancer Prevention - Washington, D.C.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hemminki, K.
Right arrow Articles by Vaittinen, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hemminki, K.
Right arrow Articles by Vaittinen, P.

Cancer Epidemiology Biomarkers & Prevention, Vol 7, Issue 10 865-868, Copyright © 1998 by American Association for Cancer Research


ARTICLES

Familial risks in in situ cancers from the Family-Cancer Database

K Hemminki and P Vaittinen
Department of Biosciences at Novum, Karolinska Institute, Huddinge, Sweden. Kari.Hemminki@cnt.ki.se

The Swedish Family-Cancer Database was used to analyze relationships between parents and offspring with in situ cancers and between in situ cancers in one generation and invasive cancer in the other generation. A total of 130,000 in situ cancers and close to 400,000 invasive cancers were included from 1959 to 1994. The data on family relationships and cancers came from registered sources and should be free from bias. The offsprings' familial relative risks (FRRs) were calculated for concordant and discordant parental cancer sites. The most common male in situ site was skin (both melanoma and precancerous epithelial lesion), whereas cervix, breast, and skin were common female sites. Increased FRRs were observed for concordant sites: colon, breast, cervix, skin (melanoma), and, in males, precancerous epithelial lesions. The findings were consistent when in situ cancer-in situ cancer and in situ cancer-invasive cancer relationships were explored. FRRs were higher for in situ colon cancer and melanoma than the respective estimates in invasive cancers, and for the remaining sites, they were equal or somewhat lower. At discordant sites, increased FRRs of in situ cancers were observed for female breast and melanoma and, at many sites, implicated in tobacco and human papilloma virus carcinogenesis, together with cervix. Family histories of in situ cancers deserve clinical attention.


This article has been cited by other articles:


Home page
Hum Mol GenetHome page
M. Engelmark, A. Beskow, J. Magnusson, H. Erlich, and U. Gyllensten
Affected sib-pair analysis of the contribution of HLA class I and class II loci to development of cervical cancer
Hum. Mol. Genet., September 1, 2004; 13(17): 1951 - 1958.
[Abstract] [Full Text] [PDF]


Home page
Arch DermatolHome page
K. Hemminki and C. Dong
Subsequent Cancers After In Situ and Invasive Squamous Cell Carcinoma of the Skin
Arch Dermatol, May 1, 2000; 136(5): 647 - 651.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
K. Hemminki, P. Vaittinen, and C. Dong
Endometrial Cancer in the Family-Cancer Database
Cancer Epidemiol. Biomarkers Prev., November 1, 1999; 8(11): 1005 - 1010.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1998 by the American Association for Cancer Research.